Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are eligible for the related core clinical study called CLC3/S1925 (confirm with trial site)
- People who have signed a consent form before enrolling, agreeing to take part in the trial in line with local and legal requirements
- People who are able and willing to complete quality of life questionnaires in either English or French — note that being unable to complete the questionnaires (for example, due to language barriers or cognitive difficulties) does not disqualify someone, but being able yet choosing not to complete them does
- People who are able to attend all required treatment visits and follow-up appointments, so that their treatment, any side effects, and progress can be fully recorded
Who may not be able to join:
- People who do not meet the eligibility criteria for the related core study CLC3/S1925 (confirm with trial site)
- People who are unwilling to sign a consent form before enrolling
- People who are able to complete the questionnaires in English or French but are unwilling to do so
- People who are not available for ongoing treatment visits, follow-up appointments, and full documentation of their care
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Matthew Cheung, Odette Cancer Centre, Sunnybrook Helath Sciences Centre, Toronto, Ontario, Canada
Phone: 613-533-6430
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine incremental cost-utility ratio of an early novel therapy approach compared to a deferred approach in Canadian patients with high-risk CLL (enrolled in the randomized component of the SWOG S1925/CLC3 study).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.